drugset / Trial / NCT06535893

Sustainable and Efficient Platform Trial of New Therapeutic Development for Early Breast Cancer

NCT06535893

RandomizedParallel-groupOpen-labelTreatment

Summary

Randomized phase II trial targeting early-stage breast cancer (stage II-III) applicable to preoperative chemotherapy (NAC), comparing standard treatment with multiple experimental treatments.

Timeline

Start
2024-07-30
Primary completion
2027-06-30
Completion
2040-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified
Subject Doxorubicin Other / unclassified
Subject Niraparib Small molecule
Background Carboplatin Small molecule
Background Paclitaxel Small molecule
Background Pembrolizumab Monoclonal antibody

Indications